FANCD2 directly inhibits DNA2 nuclease at stalled replication forks and acts as a RAD51 mediator in strand exchange by Liu, Wenpeng et al.
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Supplementary Figure 1 (Related to Figure 1). FANCD2 regulates end
resection in response to CPT.
(A-B) U2OS cells were transfected with 20 nM FANCD2 siRNA or control scrambled
siRNA. 48 hours post-transfection, cells treated with 4 mM hydroxyurea (panel a) or
1 μM CPT (panel b) for 0-8 hours. Cells were trypsinized and prepared for neutral
COMET assay. Samples were compared with one-way ANOVA (P < 0.0001). (C)
A549 cells were transfected with 40 nM FANCD2 siRNA or control scrambled siRNA
(siNC). After 48 h, 2 µM CPT was added and cells were treated for 0-8 hours.
Samples were taken and whole cell lysates (GAPDH control) were prepared for
western blot analysis after 0, 2, 4, 6, or 8 h of treatment. RPA2-p and gH2AX were
monitored as shown. The RPA2-p bands were quantified with ImageJ, and error
bars derive from standard deviation of two experiments. (D) PD20 FANCD2-/- cell
and PD20 complemented with FANCD2 (PD20:FANCD2) were treated with 2 µM
CPT or 10 µM cisplatin for 16 h. Nuclear extract was prepared and used for the
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Supplementary Figure 2 (Related to Figure S1 and Figure 2). DNA2 Depletion
reduces the phosphorylation of RPA2 in response to replication stress in the
absence of FANCD2.
(A-B) A549 cells were transfected with 12 nM FANCD2 siRNA or control scrambled siRNA
and co-transfected with 12nM indicated siRNA. After 48 h, the cells were treated with 2 µM
CPT for 1 h (acute treatment). Samples were collected and whole cell lysates were
prepared for western blot analysis. (C) Depletion of DNA2 rescues over-resection in cells
treated with cisplatin. PD20 FANCD2-/- cells were infected with empty vector or DNA2
shRNA and then selected for two days before plating equal numbers to 6 well plates. Cells
were treated with 0 µM or 10 µM cisplatin for 4 h on the following day and then harvested.
Whole cell lysate was prepared; then western blotting was performed to monitor RPA2-
S33 phosphorylation. Treatments are as indicated in the figure. For untreated control see
Figure 1A, untreated, 0 h HU. (D) and (E) A549 cells were transfected with 20 nM
FANCD2 siRNA or control scrambled siRNA and co-transfected with 20nM siRNA against
DNA2 (panel d) or CtIP(panel e) . After 48 h, the cells were treated with 2 µM CPT for 1 h
(acute stress). Samples were collected and whole cell lysates were prepared for western
blot analysis. (F) Replication fork restart. DNA2 co-depletion rescues replication fork
restart efficiency after HU or cisplatin treatment of FANCD2 defective cells. U2OS cells
were co-transfected with 12 nM indicated siRNA, respectively. 72 hours later, the cells
were pulsed labeled with CldU for 20 mins and then 4 mM HU or 1 uM cisplatin were
added for 1 hour, followed by wash out and I dU medium for 1 hour. No release indicates
add stress reagent in the IdU medium. No stress means no stress reagent added during
CldU labeling. The cells were harvested and analyzed by DNA combing assay. Restart
efficiency is calculated by restart events over sum of stalled and restart events. The
definition of restart and stalled and new fired origin events are indicated at the right of the
panel. Red, green; red, green, red; and green, red, green were counted as 1, 1, and 2
restart events, respectively. Approximately 500 fiber events were counted for each sample.
Error bar is standard deviation derived from two experiments.
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Supplementary Figure 3 (related to Figure 3). Characterization of human
FANCD2-His and validation of reversed fork substrates using RuvC.
(A) Human FANCD2-His was expressed and purified from insect cells as described
(Roques et al., 2009). Gel analysis of the protein is shown. (B) dsDNA binding by the
FANCD2-His was carried out as described (Niraj et al., 2017). (C) FANCD2 inhibits
DNA2 on ssDNA. The assay was conducted as in Figure 3C with JYM945 substrate
DNA (1.5 nM). (D) Oligonucleotides described in Supplementary Table S2 were
labeled, annealed and gel purified. The reversed fork with blunt ends consisted of 4
oligonucleotides: 5’ labeled strand 1, strand 2, strand 3, and strand 4 (van Gool et
al., 1998). The reversed fork with 5’ overhang consisted of 5’ labeled strand 1L:
strand 2, strand 3, and strand 4. 1.5 nM of the indicated substrate, 5’ end-labeled as
indicated, was incubated in a 10 µl reaction mix containing 25 nM RuvC (Abcam) or
diluent, 50 mM Tris-HCl (pH 8.0), 10 mM MgCl2, 100 μg/ mL BSA,1 mM DTT at
37°C for 30 min (Amunugama et al., 2018). Following incubations, proteinase K
and SDS were added to 1 mg/ml and 0.5% respectively and incubated for 10 min at
37°C. 1 μl of 10X native loading dye was added to final 2.5% Ficoll- 400, 10 mM
Tris-HCl (pH 7.5) and 0.0025% xylene cyanol concentrations. Samples were
separated on an 8% native gel using 29:1 30% acrylamide solution, constant voltage
200V in cold room, 1X TAE, 120 min, 5 h exposure. The labeled product on the blunt
ended reversed fork was expected to be 50 bp and 80 bp on the recessed reversed
fork.
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Supplementary Figure 4 (Related to Figure 4). Characterization of FANCD2-
F1+F3Mut mutant protein.
(A) Human FANCD2 WT and FANCD2-F1+F3 Mut-His purification gel analysis. (B)
Comparison of DNA binding by FANCD2 and FANCD2-F1+F3Mut. Reaction conditions
were as in (Niraj et al., 2017). Reactions in lanes 1-5 contained 1 nM 5’ labeled 87FORK
and reactions in lanes 6-10 contained 1 nM ssDNA: 5’ labeled JYM945* (60nt).
Imagequant quantification revealed a 10- fold reduction in FANCD2-F1+F3Mut binding
to ssDNA (lane8 vs lane 10). (C) Yeast DNA2 is not inhibited by FANCD2 – 87 fork
substrate. Conditions were the same as in panel f, except that yeast FLAG- DNA2
(Masuda-Sasa et al., 2006) was used instead of human. Note that yeast DNA2 is more
active than human DNA2 and therefore the amounts of yeast DNA2 shown are adjusted
to give £ 50% degradation of substrate.
(D) Yeast DNA2 is not inhibited by FANCD2 – reversed fork substrate. Conditions were
the same as in panel f, except that yeast FLAG-DNA2(Masuda-Sasa et al., 2006) was
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Figure S5
Supplementary Figure 5 (Related to Figure 5). RAD51 filaments also
prevent EXO1 mediated end resection.
Rad51 filaments inhibit EXO1. Indicated amounts of RAD51 were
incubated with 1.5 nM EXO1 substrate in reactions mixtures (10 μl)
containing 20 mM Tris-HCl, pH 7.6, 0.75 mM HEPES-KOH, 120 mM KCl,
250 μg/ml BSA, 2 mM ATP, 1 mM glutathione, 2 mM MgCl2, 2mM CaCl2,
1% glycerol, 0.06 mM DTT, and incubated for 10 min at 37°C. EXO1
(0.77 nM) was added and incubation continued for 30 min. RAD51 was
added as indicated. Samples were processed as in the lower panel.
120 nM Rad51 - + + + + + +
35 nM WT FD2 - - + - - + -
35 nM FD2-F1/F3Mut - - - + - - +






Supplementary Figure 6 (related to Figure 6). FANCD2 promotes
strand exchange activity of RAD51 independent of its DNA binding.
Inverse strand exchange assay. In lanes 1-4, the exchange assay was
conducted as in the legend to Figure 6A- 6C. In lanes 5-7 the double-
stranded DNA was preincubated with RAD51 and then ssDNA was
added, the inverse strand exchange assay.
